Top Markets
#1 Helium Helium +54.24%
#2 TENDIES TENDIES +42.67%
#3 Pons Pons +31.17%
#4 UnifAI Network UnifAI Network +19.26%
#5 Seeker Seeker +18.62%
#6 Songbird Songbird +12.62%
#7 Lista DAO Lista DAO +11.02%
#8 OSK OSK +10.04%
#9 DAPPOS DAPPOS +9.30%
#10 Wrapped STX (Velar) Wrapped STX (Velar) +8.97%
Coin of the day
Helium Helium
Settings
Language
ENGLISH
Currency
USD
Theme
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Rank in Stocks #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Share Price
$9.50
Last synced: 2025-01-08
Market Cap
$819.52M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Poseida Therapeutics, Inc. (PSTX)

Category

Healthcare
Stock price history for Poseida Therapeutics, Inc. (PSTX)
Highest end of day price: $9.50 on 2025-01-01

Lowest end of day price: $14.51 on 2020-07-01
Stock price history of Poseida Therapeutics, Inc. from 2020 to 2026
Annual Stock Price Performance
Year Performance
2025 0.49%
2024 201.20%
2023 -41.30%
2022 -23.11%
2021 -33.50%
2020 0.00%
Stock price for similar companies or competitors
Company Stock price Change 1y% Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH